Is Valneva (VALN) the Best Performing NASDAQ Stock So Far in 2025? [Yahoo! Finance]
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
Valneva SE (NASDAQ: VALN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA